Holen Sie sich die Stockscreener-App
34.37
3.99%
-1.43
Handel nachbörslich:
34.37
Schlusskurs vom Vortag:
$35.80
Offen:
$36.61
24-Stunden-Volumen:
914.92K
Relative Volume:
0.87
Marktkapitalisierung:
$3.90B
Einnahmen:
$14.09M
Nettoeinkommen (Verlust:
$-176.94M
KGV:
-15.99
EPS:
-2.15
Netto-Cashflow:
$-141.24M
1W Leistung:
-2.36%
1M Leistung:
-1.24%
6M Leistung:
+58.83%
1J Leistung:
+34.52%
1-Tages-Spanne:
$34.36
$37.11
1-Wochen-Bereich:
$32.66
$37.11
52-Wochen-Spanne:
$14.06
$42.00
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Firmenname
Newamsterdam Pharma Company Nv
Sektor
Branche
Telefon
35 206 2971
Adresse
GOOIMEER 2-35, NARRDEN
Vergleichen Sie NAMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
34.37 | 4.06B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-08-25 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-17 | Eingeleitet | Goldman | Neutral |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2025-06-10 | Eingeleitet | Stifel | Buy |
| 2025-06-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-15 | Eingeleitet | TD Cowen | Buy |
| 2024-03-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-01-18 | Eingeleitet | Guggenheim | Buy |
| 2024-01-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-10-30 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Newamsterdam Pharma Company Nv Aktie (NAMS) Neueste Nachrichten
NewAmsterdam Pharma outlines 2026 goals after strong 2025 progress - TipRanks
NewAmsterdam expects EMA decision on cholesterol drug in second half 2026 - Investing.com
NewAmsterdam expects EMA decision on cholesterol drug in second half 2026 By Investing.com - Investing.com South Africa
NewAmsterdam Pharma Updates on Obicetrapib Clinical Development and EMA Approval Timeline - Quiver Quantitative
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities - GlobeNewswire
Can NewAmsterdam Pharma Company N.V. stock continue upward trendModel Comparison & how to pick the right width - ulpravda.ru
Why NewAmsterdam Pharma Company N.V. Equity Warrant stock attracts high net worth investorsJuly 2025 Selloffs & Reliable Volume Spike Alerts - ulpravda.ru
Can NewAmsterdam Pharma Company N.V. (KH6) stock hold up in economic slowdownMarket Activity Summary & AI Forecasted Entry and Exit Points - ulpravda.ru
Is NewAmsterdam Pharma Company N.V. Equity Warrant stock near bottom after declineAnalyst Upgrade & Verified Chart Pattern Signals - ulpravda.ru
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock gain from strong economy2025 Historical Comparison & Community Consensus Stock Picks - ulpravda.ru
What dividend safety score for NewAmsterdam Pharma Company N.V. stock2025 Technical Patterns & Low Risk High Reward Ideas - ulpravda.ru
Is NewAmsterdam Pharma Company N.V. stock positioned for long term growthEconomic Indicators Overview & Affordable Growth Investments - ulpravda.ru
A Look At NewAmsterdam Pharma (NAMS) Valuation As Late Stage CETP Trial Progress Draws Investor Attention - Sahm
NewAmsterdam Pharma Company N.V. (NAMS) Shares Spiked by 57% in Q3 - Insider Monkey
NewAmsterdam Pharma stock price target raised to $55 by Leerink Partners - Investing.com Nigeria
NewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 6.4%Time to Sell? - MarketBeat
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma stock slides on insider sale notices — what investors watch next for NAMS - TechStock²
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Behavioral Patterns of NAMS and Institutional Flows - Stock Traders Daily
ID Info Business Services Limited Enters Reversal Setup in Weekly ChartsEconomic Indicators Overview & Target Triple-Digit Stock Opportunities - earlytimes.in
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 43,872 Shares - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 26,011 Shares of Stock - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 75,117 Shares - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $928,072.48 in Stock - MarketBeat
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells 43,872 Shares of Stock - MarketBeat
Louise Frederika Kooij Sells 75,117 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
How (NAMSW) Movements Inform Risk Allocation Models - Stock Traders Daily
Is NewAmsterdam Pharma Company NV Equity Warrant a good long term investmentUtilities Sector Analysis & Identify Ideal Buy Points With Precision - Early Times
EBITDA per share of NewAmsterdam Pharma Company N.V. – MUN:KH6 - TradingView — Track All Markets
Operating cash flow per share of NewAmsterdam Pharma Company N.V. – SWB:KH6 - TradingView — Track All Markets
(NAMS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Can NewAmsterdam Pharma Company N.V. Equity Warrant stock outperform in 2025 bull marketMarket Growth Report & Short-Term Trading Alerts - Улправда
Analyst Downgrade: Will Lee Enterprises Incorporated LE70 stock keep raising dividendsJuly 2025 Big Picture & Precise Buy Zone Identification - moha.gov.vn
How NewAmsterdam Pharma Company N.V. Equity Warrant stock trades before earningsWeekly Investment Summary & Verified Swing Trading Watchlist - Улправда
Will NewAmsterdam Pharma Company N.V. stock deliver strong dividend growthEarnings Risk Summary & Detailed Earnings Play Strategies - Улправда
Can NewAmsterdam Pharma Company N.V. stock beat market expectations this quarterQuarterly Profit Report & Real-Time Volume Spike Alerts - Улправда
Aug Selloffs: Can NewAmsterdam Pharma Company N.V. stock beat market expectations this quarterMarket Trend Review & Weekly Watchlist for Consistent Profits - Улправда
Is NewAmsterdam Pharma Company N.V. stock in correction or buying zone2025 Sector Review & Reliable Breakout Forecasts - Улправда
Is NewAmsterdam Pharma Company N.V. stock undervalued vs historical averagesJuly 2025 Technicals & Daily Stock Trend Reports - DonanımHaber
Will NewAmsterdam Pharma Company N.V. stock outperform tech sector in 20252025 Earnings Surprises & Community Trade Idea Sharing - DonanımHaber
Why NewAmsterdam Pharma Company N.V. stock attracts global investorsOptions Play & Real-Time Sentiment Analysis - DonanımHaber
Will NewAmsterdam Pharma Company N.V. stock beat EPS estimatesPortfolio Gains Report & Real-Time Stock Entry Alerts - ulpravda.ru
NewAmsterdam Pharma (NASDAQ:NAMS) Given New $50.00 Price Target at Stifel Nicolaus - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
Understanding Momentum Shifts in (NAMSW) - Stock Traders Daily
Is It Too Late To Consider NewAmsterdam Pharma After Its Strong 2025 Share Price Rally? - Yahoo Finance
Frazier Life Sciences Management L.P. Has $300.75 Million Stock Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
NewAmsterdam Pharma Company N.V. $NAMS Holdings Lifted by Maverick Capital Ltd. - MarketBeat
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Finanzdaten der Newamsterdam Pharma Company Nv-Aktie (NAMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Newamsterdam Pharma Company Nv-Aktie (NAMS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kooij Louise Frederika | Chief Accounting Officer |
Jan 05 '26 |
Sale |
33.25 |
2,647 |
88,013 |
12,353 |
| Somaiya Mayur Ian | Chief Financial Officer |
Jan 05 '26 |
Sale |
33.25 |
5,118 |
170,174 |
32,882 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):